Literature DB >> 28703395

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.

Laetitia Thibault1, Olivier Rascol2, Jean-Christophe Corvol3, Joaquim Ferreira4, Luc Defebvre5, Dominique Deplanque6, Régis Bordet6, Caroline Moreau5, David Devos6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28703395     DOI： 10.1002/mds.27055

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

Review 1.  Therapies to Slow, Stop, or Reverse Parkinson's Disease.

Authors:  Tom Foltynie; J William Langston
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

2.  Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).

Authors:  Marina Peball; Mario Werkmann; Philipp Ellmerer; Raphaela Stolz; Dora Valent; Hans-Günther Knaus; Hanno Ulmer; Atbin Djamshidian; Werner Poewe; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2019-05-25       Impact factor: 3.575

Review 3.  Prodromal Parkinson's disease: hype or hope for disease-modification trials?

Authors:  Philipp Mahlknecht; Kathrin Marini; Mario Werkmann; Werner Poewe; Klaus Seppi
Journal:  Transl Neurodegener       Date:  2022-02-21       Impact factor: 8.014

Review 4.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.